FDA Inspection Do’s and Don’ts for Life Science Companies

FDA inspections are a critical part of ensuring life science companies maintain compliance with applicable regulations and quality system requirements. Whether your organization operates in the medical device, pharmaceutical, biotechnology, diagnostic, or clinical laboratory space, FDA investigators expect companies to demonstrate control over their processes, documentation, training, and quality systems.

Many companies become overly focused on the fear of an FDA inspection rather than building sustainable inspection readiness processes. In reality, the companies that perform best during inspections are typically those with mature quality systems, strong documentation practices, and employees who understand how to interact professionally and confidently with investigators.

Below are key FDA inspection do’s and don’ts that can help organizations reduce compliance risk and improve inspection outcomes.

FDA Inspection Do’s

1. Do Prepare Before the Inspection Happens

One of the biggest mistakes companies make is treating inspection readiness as a reactive activity instead of an ongoing process.

FDA inspections can occur with little notice depending on the organization type and regulatory classification.

Preparation should include:

• Routine internal audits

• Mock FDA inspections

• Employee inspection readiness training

• CAPA reviews and effectiveness checks

• Documentation and data integrity assessments

• Supplier quality oversight

• Quality management review activities

Organizations that continuously maintain inspection readiness generally perform significantly better during inspections.

2. Do Train Employees on Inspection Conduct

Employees should understand how to interact with FDA investigators professionally and consistently.

Staff should be trained to:

• Answer questions honestly and directly

• Only answer the specific question asked

• Avoid speculation or assumptions

• Request clarification if needed

• Escalate uncertain questions appropriately

• Remain calm and professional

Inspection interactions should be factual, concise, and supported by documented evidence.

3. Do Ensure Documentation is Organized and Controlled

Poor documentation practices are one of the most common contributors to FDA 483 observations.

Companies should ensure:

• Records are complete and legible

• Documents are approved and controlled

• Training records are current

• SOPs reflect actual practices

• Forms are version controlled

• Quality records are easily retrievable

Disorganized documentation can quickly create the appearance of a weak quality system even when operations are otherwise acceptable.

4. Do Designate an Inspection Response Team

Companies should establish a defined inspection management process before an investigator arrives onsite.

An FDA inspection response team may include:

• Quality Assurance

• Regulatory Affairs

• Operations leadership

• Manufacturing representatives

• Subject matter experts

• Document coordinators

Defined responsibilities help ensure inspection activities remain organized and controlled throughout the inspection.

5. Do Conduct Mock FDA Inspections

Mock inspections help organizations identify gaps before FDA investigators do.

Benefits of mock inspections include:

• Identifying quality system weaknesses

• Improving employee confidence

• Testing document retrieval processes

• Evaluating inspection response procedures

• Assessing training effectiveness

Third-party mock inspections are especially valuable because they provide an independent assessment perspective similar to actual regulatory inspections.

FDA Inspection Don’ts

1. Don’t Guess or Speculate

If an employee does not know the answer to a question, they should not guess.

Speculative answers can create inconsistencies and additional scrutiny during the inspection.

Instead:

• State that clarification is needed

• Retrieve the correct information

• Involve the appropriate subject matter expert

• Provide documented evidence whenever possible

Accurate and controlled communication is critical during FDA inspections.

2. Don’t Provide Unrequested Information

Many companies unintentionally expand inspection scope by volunteering unnecessary information.

Employees should:

• Answer only the question asked

• Avoid overexplaining

• Avoid discussing unrelated issues

• Stay focused on factual responses

Providing excessive information can unintentionally introduce new areas of concern for investigators.

3. Don’t Attempt to Hide Problems

FDA investigators understand that no quality system is perfect.

Attempting to hide issues, alter records, or provide misleading information can significantly escalate regulatory risk and damage credibility.

Companies should instead:

• Be transparent

• Demonstrate control of identified issues

• Show ongoing remediation activities

• Present objective evidence of corrective actions

A well-managed issue is generally viewed more favorably than an undisclosed or hidden problem.

4. Don’t Wait Until the Inspection to Fix Known Gaps

Organizations sometimes postpone remediation activities until an FDA inspection becomes imminent.

This approach creates unnecessary risk.

Common examples include:

• Overdue CAPAs

• Incomplete validations

• Training gaps

• Supplier qualification deficiencies

• Uncontrolled documentation

• Open internal audit findings

Quality system issues should be addressed proactively as part of continuous improvement activities.

5. Don’t Ignore Employee Anxiety and Communication

FDA inspections can create stress across organizations, especially among employees unfamiliar with inspections.

Leadership should:

• Communicate clearly before inspections

• Reinforce expectations

• Conduct training sessions

• Promote professionalism and confidence

• Avoid creating panic or fear-based messaging

Prepared and informed employees contribute significantly to successful inspection outcomes.

Common Areas FDA Investigators Frequently Review

While inspection scope varies, investigators commonly focus on:

• CAPA systems

• Complaint handling

• Training records

• Supplier management

• Validation activities

• Change control

• Document control

• Data integrity

• Internal audits

• Management review

• Production controls

• Risk management processes

Organizations should ensure these areas are routinely reviewed internally as part of ongoing compliance activities.

Building a Sustainable Inspection Readiness Program

Successful inspection readiness programs are built on operational discipline, strong quality culture, and proactive risk management.

Effective programs often include:

• Regular gap assessments

• Internal audit programs

• Inspection readiness training

• SOP harmonization

• Quality metric reviews

• Supplier oversight

• Risk-based CAPA management

• Continuous improvement initiatives

Inspection readiness should be integrated into normal business operations rather than treated as a temporary project.

How Avendium Supports FDA Inspection Readiness

At Avendium, we support life science companies with FDA inspection readiness, quality system remediation, internal audits, mock inspections, supplier quality management, validation support, and regulatory compliance strategy.

Our team provides practical, operationally focused support tailored to medical device, biotechnology, pharmaceutical, diagnostic, and clinical laboratory organizations.

Services include:

• Mock FDA inspections

• FDA 483 remediation support

• Internal audits

• CAPA system improvement

• SOP development and remediation

• Supplier quality management

• Computer system validation